Stellate Ganglion Block to Treat Long COVID 19 Case Series

April 10, 2023 updated by: Lisa Pearson, Metamorphosis LTD

Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study

An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.

Study Type

Observational

Enrollment (Actual)

41

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Colorado
      • Cañon City, Colorado, United States, 81212
        • Metamorphosis LTD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study included 18 male and 23 females with an age range between 18 and 89 who underwent stellate ganglion block (SGB) for long COVID-19 Syndrome.

Description

Inclusion Criteria: People who scheduled themselves for a SGB in our clinics in Colorado.

-

Exclusion Criteria:

Stellate Ganglion Block Contraindications

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SGB Patients for Long COVID 19
Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics.
Procedure: Stellate Ganglion Block
Ultrasound guided block of the Stellate Ganglion with local anesthetics.
Other Names:
  • SGB

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptom Response
Time Frame: 3 months
Evaluation of the symptoms response to the Stellate Ganglion Block
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Metamorphosis LTD

Investigators

  • Principal Investigator: Lisa Pearson, DNAP, Metamorphosis LTD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Actual)

December 31, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

April 10, 2023

First Submitted That Met QC Criteria

April 10, 2023

First Posted (Actual)

April 13, 2023

Study Record Updates

Last Update Posted (Actual)

April 13, 2023

Last Update Submitted That Met QC Criteria

April 10, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SGBCOVID

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Plan to share data file

IPD Sharing Time Frame

Within a month

IPD Sharing Supporting Information Type

  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe